Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
12.41 USD +0.32% Intraday chart for Dynavax Technologies Corporation +2.56% -11.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue MT
Transcript : Dynavax Technologies Corporation, Q4 2023 Earnings Call, Feb 22, 2024
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024 CI
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Goldman Sachs Initiates Dynavax Technologies at Neutral Rating With $20 Price Target MT
Transcript : Dynavax Technologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to NASDAQ Biotechnology Index CI
Dynavax Technologies Insider Sold Shares Worth $300,000, According to a Recent SEC Filing MT
Dynavax Technologies Insider Sold Shares Worth $282,400, According to a Recent SEC Filing MT
Transcript : Dynavax Technologies Corporation, Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q3 Revenue $69.5M, vs. Street Est of $61.4M MT
Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023 CI
Dynavax Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Insider Sell: Dynavax Technologies MT
Dynavax Technologies Corporation Announces Resignation of Andrew Hack from the Board of Directors CI
Insider Sell: Dynavax Technologies MT
Insider Sell: Dynavax Technologies MT
Insider Sell: Dynavax Technologies MT
Insider Sell: Dynavax Technologies MT
JMP Securities Adjusts Price Target on Dynavax Technologies to $25 From $24, Maintains Market Outperform Rating MT
Dynavax Technologies Corporation Raises Revenue Guidance for the Full Year 2023 CI
Transcript : Dynavax Technologies Corporation, Q2 2023 Earnings Call, Aug 03, 2023
Dynavax Technologies Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart Dynavax Technologies Corporation
More charts
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B vaccine and CpG 1018. Its HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. It is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, which are focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza, and universal influenza.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.41 USD
Average target price
24.67 USD
Spread / Average Target
+98.76%
Consensus
  1. Stock
  2. Equities
  3. Stock Dynavax Technologies Corporation - Nasdaq
  4. News Dynavax Technologies Corporation
  5. Dynavax Technologies' Preliminary Q4, Full-Year 2022 Revenue for Heplisav-B and CpG 1018 Show Gains